Dr. Carolina Gandara, Head of Retina Assay Development at Newcells Biotech, leads internal and external projects within the retina platform, overseeing a team of scientists focused on creating ...

CEO Sujal Patel highlighted progress in advancing Nautilus' proteome analysis platform, focusing on targeted proteoform detection and broadscale discovery. He emphasized the tau proteoform assay's ...

Nautilus’ Iterative Mapping method enables single-molecule analysis of proteins and proteoforms and is designed to achieve comprehensive proteome coverage and detail at scale. The method empowers ...

Newcells offers a range of physiologically-relevant and functionally-validated iPSC and primary-cell models to support drug developers de-risk pre-clinical decision-making and improve clinical ...

Perceptive Discovery, the preclinical and translational services division of Perceptive, today announced a $15M series of strategic investments to expand and enhance its radiochemistry, cell assays, ...

We spoke with Scott Jones, PhD, SVP & CSO at BioBridge Global (BBG) to understand the challenges of product-specific potency ...

Freeze drying, lyophilization, and cryodesiccation are all terms used to describe the process of removing water from a sample at low temperature. This low-temperature dehydration process maximizes ...

Truetide said on Wednesday that its wholly-owned subsidiary Paraytec had launched a focused development programme aimed at establishing a high-throughput, real-time fluorescent assay to study ...

Gregory Russotti is the Chief Technology and Manufacturing Officer at Century Therapeutics, a company developing iPSC-derived, allogeneic immune cell therapy products for hematology/oncology ...

Since biological therapeutics are derived from living organisms, their manufacture and validation presents difficulties not encountered during traditional small molecule drug development. Despite the ...

New Rochelle, NY, October 17, 2025—Mary Ann Liebert, Inc., is pleased that Wai Hong (Kevin) Lo, PhD, has been appointed the new Editor-in-Chief of the journal ASSAY and Drug Development Technologies.

Early Access Program participants receive exclusive use of Nautilus’ Iterative Mapping method, initially through a validated tau proteoforms assay, with the potential to accelerate Alzheimer’s and ...